ENTITY
Sino Biopharmaceutical

Sino Biopharmaceutical (1177 HK)

168
Analysis
Health CareHong Kong
Sino Biopharmaceutical Limited, through its subsidiaries, researches, develops, produces, and sells biopharmaceutical products for the medical treatment of ophthalmia, as well as modernized Chinese medicine and chemical medicine for the treatment of hepatitis.
more
Refresh
14 Sep 2019 11:52

HK Short Interest - Diverging Healthcare

We analyse the latest SFC data released Friday evening on short position reporting in Hong Kong for the week ended 6 September.Total short notional...

Logo
401 Views
Share
22 Jul 2019 11:39

HK Connect Ideas: Ten Weeks of Inflows, Sino Biopharm, Anta, Maoyan, H&H (2019-07-19)

In our weekly HK Connect Snippet series, we aim to help our investors understand the flow of southbound trades via the Hong Kong Connect, as...

Logo
369 Views
Share
bullishTencent
15 Jul 2019 11:25

HK Connect Ideas: Nine Weeks of Inflows, Sino Biopharm, Yadea, Anta, Aoyuan (2019-07-12)

In our weekly HK Connect Snippet series, we aim to help our investors understand the flow of southbound trades via the Hong Kong Connect, as...

Logo
491 Views
Share
bullishTencent
08 Jul 2019 16:26

HK Connect Ideas: Eight Weeks of Inflows, Sinoma, Sino Biopharm, Meituan/Xiaomi (2019-07-05)

In our weekly HK Connect Snippet series, we aim to help our investors understand the flow of southbound trades via the Hong Kong Connect, as...

Logo
457 Views
Share
03 Jun 2019 04:21

Hansoh Pharma IPO: Valuation Reasonable for the Trade-Offs

Hansoh Pharmaceutical (3692 HK) claims to be one of the few R&D driven Chinese pharmaceutical companies. It announced its IPO price range of...

Logo
716 Views
Share
x